Hong Kong On 30 April 2018, Hong Kong Stock Exchange’s (HKEX’s) introduced a number of reforms to allow and support the listing of pre-profit biotech companies. Nearly 2.5 years later, 20 companies have seized the opportunity to IPO under the new Chapter 18A, raising a total of over HKD 34.92 billion (USD…
Hong Kong Shawn, as I understand, SinoMab today is a clinical stage biopharma company focusing on the development of therapeutic monoclonal antibodies (mAbs) – hence the name. Can you tell us a little about the genesis of the company? Having previously studied and worked in the UK and US, I was asked…
See our Cookie Privacy Policy Here